K. Conners

发表

Structure of nucleotide‐binding domain 1 of the cystic fibrosis transmembrane conductance regulator

J. M. Sauder, S. Burley, W. Hendrickson, 2004, The EMBO journal.

Impact of the ΔF508 Mutation in First Nucleotide-binding Domain of Human Cystic Fibrosis Transmembrane Conductance Regulator on Domain Folding and Structure*

J. M. Sauder, Xun Zhao, J. Hunt, 2005, Journal of Biological Chemistry.

Structure and dynamics of NBD1 from CFTR characterized using crystallography and hydrogen/deuterium exchange mass spectrometry.

J. M. Sauder, P. Weber, F. Lu, 2010, Journal of molecular biology.

Metabotropic Glutamate Receptor

J. F. Soriano, P. Ornstein, S. Atwell, 2016 .

Myeloid Development Is Selectively Disrupted in PU.1 Null Mice

S. Mckercher, R. Maki, B. Torbett, 1998 .

Myeloid development is selectively disrupted in PU.1 null mice.

S. Mckercher, R. Maki, B. Torbett, 1998, Blood.

Structures of a minimal human CFTR first nucleotide-binding domain as a monomer, head-to-tail homodimer, and pathogenic mutant.

John F Hunt, Diana Wetmore, Spencer Emtage, 2010, Protein engineering, design & selection : PEDS.

Computational design of highly signaling active membrane receptors through de novo solvent-mediated allosteric networks

B. Chau, M. Rutter, P. Barth, 2021, bioRxiv.

Discovery of (1S,2R,3S,4S,5R,6R)-2-Amino-3-[(3,4-difluorophenyl)sulfanylmethyl]-4-hydroxy-bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid Hydrochloride (LY3020371·HCl): A Potent, Metabotropic Glutamate 2/3 Receptor Antagonist with Antidepressant-Like Activity.

J. F. Soriano, P. Ornstein, S. Atwell, 2016, Journal of medicinal chemistry.

Structural basis for GPR40 allosteric agonism and incretin stimulation

A. R. Miller, B. Chau, T. Gheyi, 2018, Nature Communications.

Pharmacokinetics (PK) Effectiveness (E) and Tolerability (T) of Transdermal Selegiline (STS) in Children (C) and Adolescents (A) with Attention Deficit Hyperactivity Disorder (ADHD)

L. Greenhill, F. Sallee, R. Findling, 2003 .